Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Pfizer Inc at Cowen Health Care Conference Transcript

Mar 12, 2019 / 01:20PM GMT
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

We'll get started. Very happy to have Pfizer with us this year at the Cowen conference. Representing the company, Chris Boshoff, who's Senior Vice President and Chief Development Officer in the Oncology business; as well as Andy Schmeltz, who is Global President of Oncology.

Oncology is such an important business to Pfizer, and it's one part of what we think is an emerging new product story. So it's great to have you here to walk us through the many exciting developments in the company.

So they're going to present just a few slides to set the stage, and then we'll dive right into questions.

Andy Schmeltz
Pfizer Inc. - Global President, Oncology

Great. Thanks, Steve. Chris and I are very happy to be here. if you want to cue the slides up, perhaps?

Okay. So maybe make a few opening remarks and then jump in.

We're very proud in Pfizer Oncology of the strong growth trajectory over the past several years. In fact, our compound

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot